MedTrace Logo

Trial of Antroquinonol in Patients With Hypercholesterolemia and Hyperlipidemia

NCT02719028 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 120

Last updated 2020-01-02

Study results available
· View outcomes & findings →

Summary

Identified the efficacy of Antroquinonol (Hocena 50mg) in triglyceride, lipid-lowering and fatty liver.

Conditions

  • Hyperlipidemias

Interventions

DRUG

Antroquinonol

Antroquinonol will be provided as capsules of 50 mg

DRUG

placebo

The matching placebo will be packaged as Antroquinonol with appearance identical in all aspects, however, don't have the active compound(antroquinonol)

Sponsors & Collaborators

  • Golden Biotechnology Corporation

    lead INDUSTRY

Principal Investigators

  • Fu-Tien Chiang, M.D. · National Taiwan University Hopspital

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
30 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2016-05-31
Primary Completion
2018-09-27
Completion
2019-03-31

Countries

  • Taiwan

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02719028 on ClinicalTrials.gov